Title: Method of treating fibrosis
United States Patent: 6,893,637
Issued: May 17, 2005
Inventors: Gilbertson; Debra G. (Seattle, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Appl. No.: 695121
Filed: October 23, 2000
Materials and Methods for treating fibrosis in a mammal are disclosed.
The methods comprise administering to a mammal a composition comprising a
therapeutically effective amount of a zvegf3 antagonist in combination with
a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include
anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3
variant polypeptides, and inhibitory polynucleotides. Within one embodiment
of the fibrosis is liver fibrosis.
Description of the Invention
BACKGROUND OF THE INVENTION
Fibrosis is the abnormal accumulation of fibrous tissue that can occur as
a part of the wound-healing process in damaged tissue. Such tissue damage
may result from physical injury, inflammation, infection, exposure to
toxins, and other causes. Examples of fibrosis include dermal scar
formation, keloids, liver fibrosis, lung fibrosis (e.g., silicosis,
asbestosis), kidney fibrosis (including diabetic nephropathy), and
Liver (hepatic) fibrosis, for example, occurs as a part of the wound-healing
response to chronic liver injury. Fibrosis occurs as a complication of
haemochromatosis, Wilson's disease, alcoholism, schistosomiasis, viral
hepatitis, bile duct obstruction, exposure to toxins, and matabolic
disorders. This formation of scar tissue is believed to represent an attempt
by the body to encapsulate the injured tissue. Liver fibrosis is
characterized by the accumulation of extracellular matrix that can be
distinguished qualitatively from that in normal liver. Left unchecked,
hepatic fibrosis progresses to cirrhosis (defined by the presence of
encapsulated nodules), liver failure, and death.
In recent years there have been significant advances in the understanding of
the cellular and biochemical mechanisms underlying liver fibrosis (reviewed
by Li and Friedman, J. Gastroenterol. Hepatol. 14:618-633, 1999).
Stellate cells are believed to be a major source of extracellular matrix in
the liver. Stellate cells respond to a variety of cytokines present in the
liver, some of which they also produce (Friedman, Seminars in Liver
Disease 19:129-140, 1999).
As summarized by Li and Friedman (ibid.), actual and proposed therapeutic
strategies for liver fibrosis include removal of the underlying cause (e.g.,
toxin or infectious agent), suppression of inflammation (using, e.g.,
corticosteroids, IL-1 receptor antagonists, or other agents),
down-regulation of stellate cell activation using, e.g., gamma interferon or
antioxidants), promotion of matrix degradation, or promotion of stellate
cell apoptosis. Despite recent progress, many of these strategies are still
in the experimental stage, and existing therapies are aimed at suppressing
inflammation rather than addressing the underlying biochemical processes.
Thus, there remains a need in the art for materials and methods for treating
fibrosis, including liver fibrosis.
DESCRIPTION OF THE INVENTION
The present invention provides materials and methods for reducing cell
proliferation or extracellular matrix production, treating fibrosis, and
reducing stellate cell activation in a mammal.
Within one aspect of the invention there is provided a method of reducing
cell proliferation or extracellular matrix production in a mammal comprising
administering to the mammal a composition comprising a zvegf3 antagonist in
combination with a pharmaceutically acceptable delivery vehicle, wherein the
zvegf3 antagonist is selected from the group consisting of anti-zvegf3
antibodies, mitogenically inactive receptor-binding zvegf3 variant
polypeptides, and inhibitory polynucleotides, in an amount sufficient to
reduce cell proliferation or extracellular matrix production. Within certain
embodiments of the invention, proliferation of mesangial, endothelial,
smooth muscle, fibroblast, osteoblast, osteoclast, stellate, or interstitial
cells is reduced. Within other embodiments, the mammal is suffering from a
fibroproliferative disorder of the liver, kidney, or bone.
Within another aspect of the present invention there is provided a method of
treating fibrosis in a mammal comprising administering to the mammal a
composition comprising a therapeutically effective amount of a zvegf3
antagonist in combination with a pharmaceutically acceptable delivery
vehicle, wherein the zvegf3 antagonist is selected from the group consisting
of anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3
variant polypeptides, and inhibitory polynucleotides. Within certain
embodiment of the invention the fibrosis is liver fibrosis or kidney
Within a third aspect of the invention there is provided a method of
reducing stellate cell activation in a mammal comprising administering to
the mammal a composition comprising a zvegf3 antagonist in combination with
a pharmaceutically acceptable delivery vehicle, wherein the zvegf3
antagonist is selected from the group consisting of anti-zvegf3 antibodies,
mitogenically inactive receptor-binding zvegf3 variant polypeptides, and
inhibitory polynucleotides, in an amount sufficient to reduce stellate cell
activation. Within one embodiment, the stellate cells are liver stellate
Within a fourth aspect of the invention there are provided pharmaceutical
compositions for use within the above methods. In general, the compositions
comprise a zvegf3 antagonist in combination with a pharmaceutically
acceptable delivery vehicle, wherein the zvegf3 antagonist is selected from
the group consisting of anti-zvegf3 antibodies, mitogenically inactive
receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides.
The present invention provides methods for treating fibrosis in a patient
using zvegf3 antagonists. Zvegf3 is a protein that is structurally related
to platelet-derived growth factor (PDGF) and the vascular endothelial growth
factors (VEGF). This protein has also been designated "VEGF-R" (WIPO
Publication WO 99/37671) and, more recently, "PDGF-C" (WO 00/18212). Zvegf3/PDGF-C
is a multi-domain protein with significant homology to the PDGF/VEGF family
of growth factors. Representative amino acid sequences of human and mouse
zvegf3 are shown in SEQ ID NO:2 and SEQ ID NO:4, respectively. DNAs encoding
these polypeptides are shown in SEQ ID NOS:1 and 3, respectively.
The term "zvegf3 protein" is used herein to denote proteins comprising the
growth factor domain of a zvegf3 polypeptide (e.g., residues 235-345 of
human zvegf3 (SEQ ID NO:2) or mouse zvegf3 (SEQ ID NO:4)), wherein said
protein is mitogenic for cells expressing cell-surface PDGF α-receptor
subunit Zvegf3 has been found to bind to the αα and αβ isoforms of PDGF
receptor. Zvegf3 proteins include homodimers and heterodimers as disclosed
below. Using methods known in the art, zvegf3 proteins can be prepared in a
variety of forms, including glycosylated or non-glycosylated, pegylated or
non-pegylated, with or without an initial methionine residues, and as fusion
proteins as disclosed in more detail below.
Structural predictions based on the zvegf3 sequence and its homology to
other growth factors suggests that the polypeptide can form homomultimers or
heteromultimers having growth factor activity, i.e., modulating one or more
of cell proliferation, migration, differentiation, and metabolism.
Experimental evidence confirms that biologically active zvegf3 is a dimeric
protein. While not wishing to be bound by theory, the similarity of zvegf3
to other members of the PDGF/VEGF family suggests that zvegf3 may also form
heteromultimers with other members of the family, including VEGF, VEGF-B,
VEGF-C, VEGF-D, zvegf4 (SEQ ID NO:5), PIGF (Maglione et al., Proc. Natl.
Acad. Sci. USA 88:9267-9271, 1991), PDGF-A (Murray et al., U.S. Pat. No.
4,899,919; Heldin et al., U.S. Pat. No. 5,219,759), or PDGF-B (Chiu et al.,
Cell 37:123-129, 1984; Johnsson et al., EMBO J. 3:921-928,
The zvegf3 polypeptide chain comprises a growth factor domain and a CUB
domain. The growth factor domain is characterized by an arrangement of
cysteine residues and beta strands that is characteristic of the "cystine
knot" structure of the PDGF family. The CUB domain shows sequence homology
to CUB domains in the neuropilins (Takagi et al., Neuron 7:295-307,
1991; Soker et al., ibid.), human bone morphogenetic protein-i (Wozney et
al., Science 242:1528-1534, 1988), porcine seminal plasma protein and
bovine acidic seminal fluid protein (Romero et al., Nat. Struct. Biol.
4:783-788, 1997), and X. laevis tolloid-like protein (Lin et al.,
Dev. Growth Differ. 39:43-51, 1997).
An alignment of mouse and human zvegf3 polypeptide sequences is shown in
FIG. 2. Analysis of the amino acid sequence shown in SEQ ID NO:2
indicates that residues 1 to 14 form a secretory peptide. The CUB domain
extends from residue 46 to residue 163. A propeptide-like sequence extends
from residue 164 to residue 234, and includes two potential cleavage sites
at its carboxyl terminus, a dibasic site at residues 231-232 and a target
site for furin or a furin-like protease at residues 231-234. The growth
factor domain extends from residue 235 to residue 345. Those skilled in the
art will recognize that domain boundaries are somewhat imprecise and can be
expected to vary by up to +5 residues from the specified positions.
Potential proteolytic cleavage sites occur at residues 232 and 234.
Processing of recombinant zvegf3 produced in BHK cells has been found to
occur between residues 225 and 226. Signal peptide cleavage is predicted to
occur after residue 14 (±3 residues). This analysis suggests that the zvegf3
polypeptide chain may be cleaved to produce a plurality of monomeric species
as shown in Table 1. Cleavage after Arg-234 is expected to result in
subsequent removal of residues 231-234, with possible conversion of Gly-230
to an amide. Cleavage after Lys-232 is expected to result in subsequent
removal of residue 231, again with possible conversion of Gly-230 to an
amide. In addition, it may be advantageous to include up to seven residues
of the interdomain region at the carboxyl terminus of the CUB domain. The
interdomain region can be truncated at its amino terminus by a like amount.
See Table 1. Corresponding domains in mouse and other non-human zvegf3s can
be determined by those of ordinary skill in the art from sequence
||Residues (SEQ ID NO:2)
|CUB domain + interdomain region
|Cub domain + interdomain region +
|growth factor domain
|Growth factor domain
|Growth factor domain +
Zvegf3 can thus be prepared in a variety of multimeric forms comprising a
zvegf3 polypeptide as disclosed above. These zvegf3 polypeptides include
zvegf315-345, zvegf46-345, zvegf3226-345,
and zvegf3235-345. Variants and derivatives of these polypeptides
can also be prepared as disclosed herein.
Zvegf3 proteins can be prepared as fusion proteins comprising amino- or
carboxyl-terminal extensions, such as an amino-terminal methionine residue,
an affinity tag, or a targetting polypeptide. For example, a zvegf3 protein
can be prepared as a fusion with an affinity tag to facilitate purification.
In principal, any peptide or protein for which an antibody or other specific
binding agent is available can be used as an affinity tag. Affinity tags
include, for example, a poly-histidine tract, protein A (Nilsson et al.,
EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3,
1991), glutathione S transferase (Smith and Johnson, Gene 67:31,
1988), Glu—Glu affinity tag (Grussenmeyer et al., Proc. Natl. Acad. Sci.
USA 82:7952-4, 1985), substance P, Flag™ peptide (Hopp et al.,
Biotechnology 6:1204-1210, 1988), streptavidin binding peptide, maltose
binding protein (Guan et al., Gene 67:21-30, 1987), cellulose binding
protein, thioredoxin, ubiquitin, T7 polymerase, or other antigenic epitope
or binding domain. Fusion of zvegf3 to, for example, maltose binding protein
or glutatione S transferase can be used to improve yield in bacterial
expression systems. In these instances the non-zvegf3 portion of the fusion
protein ordinarily will be removed prior to use. Separation of the zvegf3
and non-zvegf3 portions of the fusion protein is facilitated by providing a
specific cleavage site between the two portions. Such methods are well known
in the art. Zvegf3 can also be fused to a targetting peptide, such as an
antibody (including polyclonal antibodies, monoclonal antibodies,
antigen-binding fragments thereof such as F(ab′)2 and Fab
fragments, single chain antibodies, and the like) or other peptidic moiety
that binds to a target tissue.
Variations can be made in the zvegf3 amino acid sequences shown in SEQ ID
NO:2 and SEQ ID NO:4 to provide mitogenically inactive, receptor-binding
polypeptides that act as zvegf3 antagonists. As used herein, the term "mitogenically
inactive" means that the protein does not show statistically significant
activity in a standard mitogenesis assay as compared to a wild-type zvegf3
control. Such variations include amino acid substitutions, deletions, and
insertions. While not wishing to be bound by theory, it is believed that
residues Arg260-Trp271 of human zvegf3 (SEQ ID NO:2) form a loop that define
the ability of the protein to bind to PDGF-β receptors, although binding is
also permitted to alpha receptors. It is thus predicted that binding to
either receptor subunit can be blocked or enhanced by mutations in this
region. In addition, residues Leu311-His321 of SEQ ID NO:2 are predicted to
form a loop (loop3) that may be mutated to block receptor binding. Peptides
that mimic this region of the molecule may act as antagonists.
The effects of amino acid sequence changes can be predicted by computer
modeling (using, e.g., the Insight II® viewer and homology modeling tools;
MSI, San Diego, Calif.) or determined by analysis of crystal structure (see,
e.g., Lapthorn et al., Nature 369:455, 1994), and can be assessed
using art-recognized mutagenesis procedures in combination with activity
assays. Representative mutagenesis procedures include, for example,
site-directed mutagenesis and alanine-scanning mutagenesis (Cunningham and
Wells, Science 244, 1081-1085, 1989; Bass et al., Proc. Natl.
Acad. Sci. USA 88:44984502, 1991). Multiple amino acid substitutions can
be made and tested using known methods, such as those disclosed by Reidhaar-Olson
and Sauer (Science 241:53-57, 1988) or Bowie and Sauer (Proc.
Natl. Acad Sci. USA 86:2152-2156, 1989). Other methods that can be used
include phage display (e.g., Lowman et al., Biochem 30:10832-10837,
1991; Ladner et al., U.S. Pat. No. 5,223,409; Huse, WIPO Publication WO
92/06204), region-directed mutagenesis (Derbyshire et al., Gene
46:145, 1986; Ner et al., DNA 7:127, 1988), and DNA shuffling as disclosed
by Stemmer (Nature 370:389-391, 1994) and Stemmer (Proc. Natl.
Acad. Sci. USA 91:10747-10751, 1994). The resultant mutant molecules are
tested for mitogenic activity or other properties (e.g., receptor binding)
to identify amino acid residues that are critical to these functions.
Mutagenesis can be combined with high volume or high-throughput screening
methods to detect biological activity of zvegf3 variant polypeptides, in
particular biological activity in modulating cell proliferation. For
example, mitogenesis assays that measure dye incorporation or 3H-thymidine
incorporation can be carried out on large numbers of samples. Competition
assays can be employed to confirm antagonist activity.
Zvegf3 proteins, including full-length polypeptides, fragments, and fusion
proteins, can be produced in genetically engineered host cells according to
conventional techniques. Suitable host cells are those cell types that can
be transformed or transfected with exogenous DNA and grown in culture, and
include bacteria, fungal cells, and cultured higher eukaryotic cells
(including cultured cells of multicellular organisms). Techniques for
manipulating cloned DNA molecules and introducing exogenous DNA into a
variety of host cells are disclosed by Sambrook et al., Molecular
Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, N.Y., 1989, and Ausubel et al., eds., Current
Protocols in Molecular Biology, Green and Wiley and Sons, NY, 1993. See,
WO 00/34474. In general, a DNA sequence encoding a zvegf3 polypeptide is
operably linked to other genetic elements required for its expression,
generally including a transcription promoter and terminator, within an
expression vector. The vector will also commonly contain one or more
selectable markers and one or more origins of replication, although those
skilled in the art will recognize that within certain systems selectable
markers may be provided on separate vectors, and replication of the
exogenous DNA may be provided by integration into the host cell genome.
Selection of promoters, terminators, selectable markers, vectors and other
elements is a matter of routine design within the level of ordinary skill in
the art. Many such elements are described in the literature and are
available through commercial suppliers. See, WO 00/34474.
Zvegf3 proteins can also comprise non-naturally occurring amino acid
residues. Non-naturally occurring amino acids include, without limitation,
trans-3-methylproline, 2,4-methanoproline, cis-4-hydroxyproline,
trans-4-hydroxyproline, N-methylglycine, allo-threonine, methylthreonine,
hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine,
homoglutamine, pipecolic acid, tert-leucine, norvaline, 2-azaphenylalanine,
3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several
methods are known in the art for incorporating non-naturally occurring amino
acid residues into proteins. For example, an in vitro system can be employed
wherein nonsense mutations are suppressed using chemically aminoacylated
suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating
tRNA are known in the art. Transcription and translation of plasmids
containing nonsense mutations is carried out in a cell-free system
comprising an E. coli S30 extract and commercially available enzymes
and other reagents. Proteins are purified by chromatography. See, for
example, Robertson et al., J. Am. Chem. Soc. 113:2722, 1991; Ellman
et al., Methods Enzymol. 202:301, 1991; Chung et al., Science
259:806-809, 1993; and Chung et al., Proc. Natl. Acad. Sci. USA
90:10145-10149, 1993). In a second method, translation is carried out in
Xenopus oocytes by microinjection of mutated mRNA and chemically
aminoacylated suppressor tRNAs (Turcatti et al., J. Biol. Chem.
271:19991-19998, 1996). Within a third method, E. coli cells are
cultured in the absence of a natural amino acid that is to be replaced
(e.g., phenylalanine) and in the presence of the desired non-naturally
occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine,
4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring
amino acid is incorporated into the protein in place of its natural
counterpart. See, Koide et al., Biochem. 33:7470-7476, 1994.
Naturally occurring amino acid residues can be converted to non-naturally
occurring species by in vitro chemical modification. Chemical modification
can be combined with site-directed mutagenesis to further expand the range
of substitutions (Wynn and Richards, Protein Sci. 2:395-403, 1993).
Zvegf3 polypeptides or fragments thereof can also be prepared through
chemical synthesis according to methods known in the art, including
exclusive solid phase synthesis, partial solid phase methods, fragment
condensation or classical solution synthesis. See, for example, Merrifield,
J. Am. Chem. Soc. 85:2149, 1963; Stewart et al., Solid Phase
Peptide Synthesis (2nd edition), Pierce Chemical Co., Rockford, Ill.,
1984; Bayer and Rapp, Chem. Pept. Prot. 3:3, 1986; and Atherton et
al., Solid Phase Peptide Synthesis: A Practical Approach, IRL Press,
Zvegf3 proteins are purified by conventional protein purification methods,
typically by a combination of chromatographic techniques. See, in general,
Affinity Chromatography: Principles & Methods, Pharmacia LKB
Biotechnology, Uppsala, Sweden, 1988; and Scopes, Protein Purification:
Principles and Practice, Springer-Verlag, New York, 1994. Proteins
comprising a polyhistidine affinity tag (typically about 6 histidine
residues) are purified by affinity chromatography on a nickel chelate resin.
See, for example, Houchuli et al., Bio/Technol. 6: 1321-1325, 1988.
Furthermore, the growth factor domain itself binds to nickel resin at pH
7.0-8.0 and 25 mM Na phosphate, 0.25 M NaCl. Bound protein can be eluted
with a descending pH gradient down to pH 5.0 or an imidazole gradient.
Recombinant zvegf3 growth factor domain protein can be purified using a
combination of chromatography on a strong cation exchanger followed by a
tandem column array comprising a strong anion exchanger followed by an
immobilized metal affinity column in series. It has also been found that
zvegf3 binds to various dye matrices (e.g., BLUE1, BLUE 2, ORANGE 1, ORANGE
3, and RED3 from Lexton Scientific, Signal Hill, Calif.) in PBS at pH 6-8,
from which the bound protein can be eluted in 1-2 M NaCl in 20 mM boric acid
buffer at pH 8.8. Protein eluted from RED3 may be passed over RED2 (Lexton
Scientific) to remove remaining contaminants. Proteins comprising a glu—glu
tag can be purified by immunoaffinity chromatography according to
conventional procedures. See, for example, Grussenmeyer et al., ibid.
Maltose binding protein fusions are purified on an amylose column according
to methods known in the art.
As disclosed in more detail below, overexpression of zvegf3 in the livers of
transgenic mice led to marked stellate cell activation and proliferation. At
8 weeks of age there was an accumulation of perisinusiodal extracellular
matrix (ECM) that progressed to a perivenular ECM deposition at 22 weeks and
possible eary stages of cirrhosis characterized by fibrotic banding and
hepatic nodule formation at 33 weeks of age. Thus, zvegf3 dimers appear to
resemble the previously described PDGF isoforms in being potent mitogens of
hepatic stellate cells and appearing to play a role in liver fibrosis. These
transgenic mice thus provide a model for testing zvegf3 antagonists as well
as other antifibrotic agents. In view of these and other experiments
disclosed herein, it is expected that altered zvegf3 expression may initiate
or exacerbate a variety of fibrotic conditions. In this context, inhibiting
the action of zvegf3 using a zvegf3 antagonist will limit the progress of
such conditions. While not wishing to be bound by theory, it is believed
that the pro-fibrotic effects of zvegf3 are due at least in part to the
induction of TGF-β production.
Zvegf3 antagonists include, without limitation, anti-zvegf3 antibodies
(including neutralizing antibodies), inhibitory polynucleotides (including
antisense polynucleotides, ribozymes, and external guide sequences), and
other peptidic and non-peptidic agents, including small molecule inhibitors
and mitogenically inactive receptor-binding zvegf3 polypeptides. Such
antagonists can be use to block the mitogenic effects of zvegf3 and thereby
reduce, inhibit, prevent, or otherwise treat fibrosis, including, without
limitation, scar formation, keloids, scleroderma, liver fibrosis, lung
fibrosis, kidney fibrosis, pancreatic fibrosis, myelofibrosis, post-surgical
fibrotic adhesions, fibroproliferative disorders of the vasculature,
fibroproliferative disorders of the prostate, fibroproliferative disorders
of bone, fibromatosis, fibroma, fibrosarcoma, and the like.
Of particular interest is the use of zvegf3 or zvegf3 antagonists for the
treatment or repair of liver damage, including damage due to chronic liver
disease, including chronic active hepatitis (including hepatitis C) and many
other types of cirrhosis. Widespread, massive necrosis, including
destruction of virtually the entire liver, can be caused by, inter alia,
fulminant viral hepatitis; overdoses of the analgesic acetaminophen;
exposure to other drugs and chemicals such as halothane, monoamine oxidase
inhibitors, agents employed in the treatment of tuberculosis, phosphorus,
carbon tetrachloride, and other industrial chemicals. Conditions associated
with ultrastructural lesions that do not necessarily produce obvious liver
cell necrosis include Reye's syndrome in children, tetracycline toxicity,
and acute fatty liver of pregnancy. Cirrhosis, a diffuse process
characterized by fibrosis and a conversion of normal architecture into
structurally abnormal nodules, can come about for a variety reasons
including alcohol abuse, post necrotic cirrhosis (usually due to chronic
active hepatitis), biliary cirrhosis, pigment cirrhosis, cryptogenic
cirrhosis, Wilson's disease, and alpha-1-antitrypsin deficiency. In cases of
liver fibrosis it may be beneficial to administer a zvegf3 antagonist to
suppress the activation of stellate cells, which have been implicated in the
production of extracellular matrix in fibrotic liver (Li and Friedman,
Fibrotic disorders of the kidney include, without limitation,
glomerulonephritis (including membranoproliferative, diffuse proliferative,
rapidly progressive, and chronic forms), diabetic glomerulosclerosis, focal
glomerulosclerosis, diabetic nephropathy, lupus nephritis,
tubulointerstitial fibrosis, membranous nephropathy, amyloidosis (which
affects the kidney among other tissues), renal arteriosclerosis, and
nephrotic syndrome. The glomerulus is a major target of many types of renal
injury, including immunologic (e.g., immune-complex- or T-cell-mediated),
hemodynamic (systemic or renal hypertension), metabolic (e.g., diabetes),
"atherosclerotic" (accumulation of lipids in the glomerulus), infiltrative
(e.g., amyloid), and toxic (e.g., snake venom) (Johnson, Kidney Int.
45:1769-1782, 1994). The renal structural changes in patients with diabetic
nephropathy include hypertrophy of the glomerulus, thickening of the
glomerular and tubular membranes (due to accumulated matrix), and increased
amounts of matrix in the measangium and tubulointerstitium (Ziyadeh et al.,
Proc. Natl. Acad. Sci. USA 97:8015-8020, 2000). Glomerular
hypertension due to intrarenal hemodynamic changes in diabetes can
contribute to the progression of diabetic nephropathy (Ishida et al.,
Diabetes 48:595-602, 1999). Autoimmune nephritis can also lead to altered
mesangial cell growth responses (Liu and Ooi, J. Immunol.
151:2247-2251, 1993). Infection by hepatitis-C virus can also result in
idiopathic membranoproliferative glomerulonephritis (Johnson et al., N.
Engl. J. Med. 328:465470, 1993). While not wishing to be bound by
theory, experiments have shown that the activity of zvegf3 is mediated by
the αα and αβ PDGF receptor isoforms. PDGF receptors are widely expressed in
most renal cell types, and their expression is upregulated in a number of
kidney pathologies (e.g., Iida et al., Proc. Natl. Acad. Sci. USA
88:6560-6564, 1991). Stimulation of PDGF receptors has been implicated in
fibroproliferative diseases of the kidney in a variety of animal models
(e.g., Ooi et al., P.S.E.B.M. 213:230-237, 1996; Lindahl et al.,
Development 125:3313-3322, 1998; Lindahl and Betsholtz, Curr. Op. Nephr.
Hypert. 7:21-26, 1998; and Betsholtz and Raines, Kidney Int.
Fibrotic disorders of the lung include, for example, silicosis, asbestosis,
idiopathic pulmonary fibrosis, bronchiolitis obliterans-organizing
pneumonia, pulmonary fibrosis associated with high-dose chemotherapy,
idiopathic pulmonary fibrosis, and pulmonary hypertension. These diseases
are characterized by cell proliferation and increased production of
extracellular matrix components, such as collagens, elastin, fibronectin,
Pancreatic fibrosis occurs in chronic pancreatitis. This condition is
characterized by duct calcification and fibrosis of the pancreatic
parenchyma. Like liver cirrhosis, chronic pancreatitis is associated with
alcohol abuse. See, Fogar et al., J. Medicine 29:277-287, 1998.
Diseases of the skeleton that are due to modified growth and matrix
production in the bone include, but are not limited to, osteopetrosis,
hyperostosis, osteosclerosis, osteoarthritis, and endosteal bone formation
in metastatic prostate cancer. Fibroproliferative disorders of bone are
characterized by aberrant and ectopic bone formation, commonly seen as
active proliferation of the major cell types participating in bone formation
as well as elaboration by those cells of a complex bone matrix. Exemplary of
such bone disorders is the fibrosis that occurs with prostate tumor
metastases to the axial skeleton. In prostate tumor-related cancellous bone
growth, prostate carcinoma cells can interact reciprocally with osteoblasts
to produce enhanced tumor growth and osteoblastic action when they are
deposited in bone (Zhau et al., Cancer 88:2995-3001, 2000; Ritchie et
al., Endocrinology 138:1145-1150, 1997). Fibroproliferative responses
of the bone originating in the skeleton per se include ostepetrosis and
hyperstosis. A defect in osteoblast differentiation and function is thought
to be a major cause in osteopetrosis, an inherited disorder characterized by
bone sclerosis due to reduced bone resorption, marrow cavities fail to
develop, resulting in extramedullary hematopoiesis and severe hematologic
abnormalities associated with optic atrophy, deafness, and mental
retardation (Lajeunesse et al., J. Clin Invest. 98:1835-1842, 1996).
In osteoarthritis, bone changes are known to occur, and bone collagen
metabolism is increased within osteoarthritic femoral heads. The greatest
changes occur within the subchondral zone, supporting a greater proportion
of osteoid in the diseased tissue (Mansell and Bailey, J. Clin. Invest.
101:1596-1603, 1998). As shown in more detail below, zvegf3 has been
found to be produced by prostate cells and to stimulate an osteoblast cell
Fibroproliferative disorders of the vasculature include, for example,
transplant vasculopathy, which is a major cause of chronic rejection of
heart transplantation. Transplant vasculopathy is characterized by
accelerated atherosclerotic plaque formation with diffuse occlusion of the
coronary arteries, which is a "classic" fibroproliferative disease. See,
Miller et al., Circulation 101:1598-1605, 2000).
Antibodies used as zvegf3 antagonists include antibodies that specifically
bind to a zvegf3 protein and, by so binding, reduce or prevent the binding
of zvegf3 protein to the receptor and, consequently, reduce or block the
receptor-mediated activity of zvegf3. As used herein, the term "antibodies"
includes polyclonal antibodies, affinity-purified polyclonal antibodies,
monoclonal antibodies, and antigen-binding fragments, such as F(ab′)2
and Fab proteolytic fragments. Genetically engineered intact antibodies or
fragments, such as chimeric antibodies, Fv fragments, single chain
antibodies and the like, as well as synthetic antigen-binding peptides and
polypeptides, are also included. Non-human antibodies may be humanized by
grafting non-human CDRs onto human framework and constant regions, or by
incorporating the entire non-human variable domains (optionally "cloaking"
them with a human-like surface by replacement of exposed residues, wherein
the result is a "veneered" antibody). In some instances, humanized
antibodies may retain non-human residues within the human variable region
framework domains to enhance proper binding characteristics. Through
humanizing antibodies, biological half-life may be increased, and the
potential for adverse immune reactions upon administration to humans is
reduced. Monoclonal antibodies can also be produced in mice that have been
genetically altered to produce antibodies that have a human structure.
Methods for preparing and isolating polyclonal and monoclonal antibodies are
well known in the art. See, for example, Cooligan et al. (eds.), Current
Protocols in Immunology, National Institutes of Health, John Wiley and
Sons, Inc., 1995; Sambrook et al., Molecular Cloning: A Laboratory Manual,
second edition, Cold Spring Harbor, N.Y., 1989; and Hurrell (ed.),
Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press,
Inc., Boca Raton, Fla., 1982. As would be evident to one of ordinary skill
in the art, polyclonal antibodies can be generated by inoculating a variety
of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens,
rabbits, mice, and rats with a zvegf3 polypeptide or a fragment thereof.
Immunogenic polypeptides will comprise an epitope-bearing portion of a
zvegf3 polypeptide (e.g., as shown in SEQ ID NO:2) or receptor. An "epitope"
is a region of a protein to which an antibody can bind. See, for example,
Geysen et at., Proc. Natl. Acad. Sci. USA 81:39984002, 1984. Epitopes
can be linear or conformational, the latter being composed of discontinuous
regions of the protein that form an epitope upon folding of the protein.
Linear epitopes are generally at least 6 amino acid residues in length.
Relatively short synthetic peptides that mimic part of a protein sequence
are routinely capable of eliciting an antiserum that reacts with the
partially mimicked protein. See, Sutcliffe et al., Science
219:660-666, 1983. Immunogenic, epitope-bearing polypeptides contain a
sequence of at least six, often at least nine, more often from 15 to about
30 contiguous amino acid residues of a zvegf3 protein. Polypeptides
comprising a larger portion of a zvegf3 protein, i.e. from 30 to 50 residues
up to the entire sequence are included. It is preferred that the amino acid
sequence of the epitope-bearing polypeptide is selected to provide
substantial solubility in aqueous solvents, that is the sequence includes
relatively hydrophilic residues, and hydrophobic residues are substantially
avoided. Such regions include residues 43-48, 96-101, 97-102, 260-265, and
330-335 of SEQ ID NO:2. As noted above, it is generally preferred to use
somewhat longer peptides as immunogens, such as a peptide comprising
residues 80-104, 299-314, and 299-326 of SEQ ID NO:2. The latter peptide can
be prepared with an additional N-terminal Cys residue to facilitate
The immunogenicity of a polypeptide immunogen may be increased through the
use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete
or incomplete adjuvant. Polypeptides useful for immunization also include
fusion polypeptides, such as fusions of a zvegf3 polypeptide or a portion
thereof with an immunoglobulin polypeptide or with maltose binding protein.
If the polypeptide portion is "hapten-like", such portion may be
advantageously joined or linked to a macromolecular carrier (such as keyhole
limpet hemocyanin (KLH), bovine serum albumin (BSA), or tetanus toxoid) for
Alternative techniques for generating or selecting antibodies include in
vitro exposure of lymphocytes to a polypeptide immunogen, and selection of
antibody display libraries in phage or similar vectors (for instance,
through use of immobilized or labeled polypeptide). Techniques for creating
and screening such random peptide display libraries are known in the art
(e.g., Ladner et al., U.S. Pat. No. 5,223,409; Ladner et al., U.S. Pat. No.
4,946,778; Ladner et al., U.S. Pat. No. 5,403,484 and Ladner et al., U.S.
Pat. No. 5,571,698), and random peptide display libraries and kits for
screening such libraries are available commercially, for instance from
Clontech Laboratories (Palo Alto, Calif.), Invitrogen Inc. (San Diego,
Calif.), New England Biolabs, Inc. (Beverly, Mass.), and Pharmacia LKB
Biotechnology Inc. (Piscataway, N.J.). Random peptide display libraries can
be screened using the zvegf3 sequences disclosed herein to identify proteins
which bind to zvegf3.
Antibodies are determined to be specifically binding if they bind to their
intended target (e.g., zvegf3 protein or receptor) with an affinity at least
10-fold greater than the binding affinity to control (e.g., non-zvegf3 or
non-receptor) polypeptide or protein. In this regard, a "non-zvegf3
polypeptide" includes the related molecules VEGF, VEGF-B, VEGF-C, VEGF-D,
PIGF, PDGF-A, and PDGF-B, but excludes zvegf3 polypeptides from non-human
species. Due to the high level of amino acid sequence identity expected
between zvegf3 orthologs, antibodies specific for human zvegf3 may also bind
to zvegf3 from other species. The binding affinity of an antibody can be
readily determined by one of ordinary skill in the art, for example, by
Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci. 51: 660-672,
1949). Methods for screening and isolating specific antibodies are well
known in the art. See, for example, Paul (ed.), Fundamental Immunology,
Raven Press, 1993; Getzoff et al., Adv. in Immunol. 43:1-98, 1988;
Goding (ed.), Monoclonal Antibodies: Principles and Practice,
Academic Press Ltd., 1996; Benjamin et al., Ann. Rev. Immunol.
Binding affinity can also be determined using a commercially available
biosensor instrument (BIAcore™, Pharmacia Biosensor, Piscataway, N.J.),
wherein protein is immobilized onto the surface of a receptor chip. See,
Karlsson, J. Immunol. Methods 145:229-240, 1991 and Cunningham and Wells,
J. Mol. Biol. 234:554-563, 1993. This system allows the determination of
on- and off-rates, from which binding affinity can be calculated, and
assessment of stoichiometry of binding.
A variety of assays known to those skilled in the art can be utilized to
detect antibodies that specifically bind to zvegf3 proteins or receptors.
Exemplary assays are described in detail in Antibodies: A Laboratory
Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press,
1988. Representative examples of such assays include: concurrent
immunoelectrophoresis, radioimmunoassay, radioimmuno-precipitation,
enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assays,
inhibition or competition assays, and sandwich assays.
For therapeutic applications it is generally preferred to use neutralizing
antibodies. As used herein, the term "neutralizing antibody" denotes an
antibody that inhibits at least 50% of the biological activity of the
cognate antigen when the antibody is added at a 1000-fold molar access.
Those of skill in the art will recognize that greater neutralizing activity
is sometimes desirable, and antibodies that provide 50% inhibition at a
100-fold or 10-fold molar access may be advantageously employed.
Zvegf3 antagonists further include antisense polynucleotides, which can be
used to inhibit zvegf3 gene transcription and thereby inhibit cell
activation and/or proliferation in vivo. Polynucleotides that are
complementary to a segment of a zvegf3-encoding polynucleotide (e.g., a
polynucleotide as set forth in SEQ ID NO:1) are designed to bind to
zvegf3-encoding mRNA and to inhibit translation of such mRNA. Antisense
polynucleotides can be targetted to specific tissues using a gene therapy
approach with specific vectors and/or promoters, such as viral delivery
systems as disclosed in more detail below.
Ribozymes can also be used as zvegf3 antagonists within the present
invention. Ribozymes are RNA molecules that contain a catalytic center and a
target RNA binding portion. The term includes RNA enzymes, self-splicing
RNAs, self-cleaving RNAs, and nucleic acid molecules that perform these
catalytic functions. A ribozyme selectively binds to a target RNA molecule
through complementary base pairing, bringing the catalytic center into close
proximity with the target sequence. The ribozyme then cleaves the target RNA
and is released, after which it is able to bind and cleave additional
molecules. A nucleic acid molecule that encodes a ribozyme is termed a "ribozyme
gene." Ribozymes can be designed to express endonuclease activity that is
directed to a certain target sequence in a mRNA molecule (see, for example,
Draper and Macejak, U.S. Pat. No. 5,496,698, McSwiggen, U.S. Pat. No.
5,525,468, Chowrira and McSwiggen, U.S. Pat. No. 5,631,359, and Robertson
and Goldberg, U.S. Pat. No. 5,225,337). An expression vector can be
constructed in which a regulatory element is operably linked to a nucleotide
sequence that encodes a ribozyme.
In another approach, expression vectors can be constructed in which a
regulatory element directs the production of RNA transcripts capable of
promoting RNase P-mediated cleavage of mRNA molecules that encode a zvegf3
polypeptide. According to this approach, an external guide sequence can be
constructed for directing the endogenous ribozyme, RNase P, to a particular
species of intracellular mRNA, which is subsequently cleaved by the cellular
ribozyme (see, for example, Altman et al., U.S. Pat. No. 5,168,053; Yuan et
al., Science 263:1269, 1994; Pace et al., WIPO Publication No. WO
96/18733; George et al., WIPO Publication No. WO 96/21731; and Werner et
al., WIPO Publication No. WO 97/33991). An external guide sequence generally
comprises a ten- to fifteen-nucleotide sequence complementary to zvegf3
mRNA, and a 3′-NCCA nucleotide sequence, wherein N is preferably a purine.
The external guide sequence transcripts bind to the targeted mRNA species by
the formation of base pairs between the mRNA and the complementary external
guide sequences, thus promoting cleavage of mRNA by RNase P at the
nucleotide located at the 5′-side of the base-paired region.
The growth factor domain of zvegf3 has been found to be the active (PDGF
receptor-binding) species of the molecule. Proteolytic processing to remove
the N-terminal portion of the molecule is required for activation. Thus,
inhibitors of this proteolytic activation can also be used as zvegf3
antagonists within the present invention.
For pharmaceutical use, zvegf3 antagonists are formulated for topical or
parenteral, particularly intravenous or subcutaneous, delivery according to
conventional methods. In general, pharmaceutical formulations will include a
zvegf3 antagonist in combination with a pharmaceutically acceptable vehicle,
such as saline, buffered saline, 5% dextrose in water, or the like.
Formulations may further include one or more excipients, preservatives,
solubilizers, buffering agents, albumin to prevent protein loss on vial
surfaces, etc. Methods of formulation are well known in the art and are
disclosed, for example, in Remington: The Science and Practice of
Pharmacy, Gonda, ed., Mack Publishing Co., Easton, Pa., 19th ed., 1995.
A "therapeutically effective amount" of a composition is that amount that
produces a statistically significant effect, such as a statistically
significant reduction in disease progression or a statistically significant
improvement in organ function. The exact dose will be determined by the
clinician according to accepted standards, taking into account the nature
and severity of the condition to be treated, patient traits, etc.
Determination of dose is within the level of ordinary skill in the art. The
therapeutic formulations will generally be administered over the period
required to achieve a beneficial effect, commonly up to several months and,
in treatment of chronic conditions, for a year or more. Dosing is daily or
intermittently over the period of treatment. Intravenous administration will
be by bolus injection or infusion over a typical period of one to several
hours. Sustained release formulations can also be employed. For treatment of
pulmonary fibrosis, a zvegf3 antagonist can be delivered by aerosolization
according to methods known in the art. See, for example, Wang et al., U.S.
Pat. No. 5,011,678; Gonda et al., U.S. Pat. No. 5,743,250, and Lloyd et al.,
U.S. Pat. No. 5,960,792.
Other mitogenic factors, including EGF, TGFβ, and FGF, have been implicated
in the initiation or perpetuation of fibrosis. It may therefore be
advantageous to combine a zvegf3 inhibitor with one or more inhibitors of
these other factors.
Antibodies are preferably administered parenterally, such as by bolus
injection or infusion (intravenous, intramuscular, intraperitoneal or
subcutaneous) over the course of treatment. Antibodies are generally
administered in an amount suficient to provide a minimum circulating level
of antibody throughout the treatment period of between approximately 20 μg
and 1 mg/kg body weight. In this regard, it is preferred to use antibodies
having a circulating half-life of at least 12 hours, preferably at least 4
days, more preferably up to 14-21 days. Chimeric and humanized antibodies
are expected to have circulatory half-lives of up to four and up to 14-21
days, respectively. In many cases it will be preferable to administer daily
doses during a hospital stay, followed by less frequent bolus injections
during a period of outpatient treatment. Antibodies can also be delivered by
slow-release delivery systems, pumps, and other known delivery systems for
continuous infusion. Dosing regimens may be varied to provide the desired
circulating levels of a particular antibody based on its pharmacokinetics.
Thus, doses will be calculated so that the desired circulating level of
therapeutic agent is maintained. Daily doses referred to above may be
administered as larger, less frequent bolus administrations to provide the
recited dose averaged over the term of administration.
Those skilled in the art will recognize that the same principles will guide
the use of other zvegf3 antagonists. The dosing regimen for a given
antagonist will be determined by a number of factors including potency,
pharmacokinetics, and the physicochemical nature of the antagonist. For
example, non-peptidic zvegf3 antagonists may be administered enterally.
Therapeutic polynucleotides, such as antisense polynucleotides, can be
delivered to patients or test animals by way of viral delivery systems.
Exemplary viruses for this purpose include adenovirus, herpesvirus,
retroviruses, vaccinia virus, and adeno-associated virus (AAV). Adenovirus,
a double-stranded DNA virus, is currently the best studied gene transfer
vector for delivery of heterologous nucleic acids. For review, see Becker et
al., Meth. Cell Biol. 43:161-89, 1994; and Douglas and Curiel,
Science & Medicine 4:4453, 1997. The adenovirus system offers
several advantages. Adenovirus can (i) accommodate relatively large DNA
inserts; (ii) be grown to high-titer; (iii) infect a broad range of
mammalian cell types; and (iv) be used with many different promoters
including ubiquitous, tissue specific, and regulatable promoters. Because
adenoviruses are stable in the bloodstream, they can be administered by
By deleting portions of the adenovirus genome, larger inserts (up to 7 kb)
of heterologous DNA can be accommodated. These inserts can be incorporated
into the viral DNA by direct ligation or by homologous recombination with a
co-transfected plasmid. When intravenously administered to intact animals,
adenovirus primarily targets the liver. If the adenoviral delivery system
has an E1 gene deletion, the virus cannot replicate in the host cells.
However, the host's tissue (e.g., liver) will express and process (and, if a
signal sequence is present, secrete) the heterologous protein.
An alternative method of gene delivery comprises removing cells from the
body and introducing a vector into the cells as a naked DNA plasmid. The
transformed cells are then re-implanted in the body. Naked DNA vectors are
introduced into host cells by methods known in the art, including
transfection, electroporation, microinjection, transduction, cell fusion,
DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of
a DNA vector transporter. See, Wu et al., J. Biol. Chem.
263:14621-14624, 1988; Wu et al., J. Biol. Chem. 267:963-967, 1992;
and Johnston and Tang, Meth. Cell Biol. 43:353-365, 1994.
Activity of zvegf3 antagonists can be measured in vitro using assays
(including cell-based assays) designed to measure zvegf3 activity.
Antagonists will reduce the effects of zvegf3 within the assay. Ligand-receptor
binding can be assayed by a variety of methods well known in the art,
including receptor competition assays (Bowen-Pope and Ross, Methods
Enzymol. 109:69-100, 1985) and through the use of soluble receptors,
including receptors produced as IgG fusion proteins (U.S. Pat. No.
5,750,375). Receptor binding assays can be performed on cell lines that
contain known cell-surface receptors for evaluation. The receptors can be
naturally present in the cell, or can be recombinant receptors expressed by
genetically engineered cells. Mitogenic activity can be measured using known
assays, including 3H-thymidine incorporation assays (as disclosed
by, e.g., Raines and Ross, Methods Enzymol. 109:749-773, 1985 and
Wahl et al., Mol. Cell Biol. 8:5016-5025, 1988), dye incorporation
assays (as disclosed by, for example, Mosman, J. Immunol. Meth.
65:55-63, 1983 and Raz et al., Acta Trop. 68:139-147, 1997) or cell
counts. Suitable mitogenesis assays measure incorporation of 3H-thymidine
into (1) 20% confluent cultures to look for the ability of zvegf3 proteins
to further stimulate proliferating cells, and (2) quiescent cells held at
confluence for 48 hours to look for the ability of zvegf3 proteins to
overcome contact-induced growth inhibition. Suitable dye incorporation
assays include measurement of the incorporation of the dye Alamar blue (Raz
et al., ibid.) into target cells. See also, Gospodarowicz et al., J.
Cell. Biol. 70:395405, 1976; Ewton and Florini, Endocrinol.
106:577-583, 1980; and Gospodarowicz et al., Proc. Natl. Acad. Sci. USA
The biological activities of zvegf3 antagonists can be studied in non-human
animals by administration of exogenous compounds, by expression of zvegf3
antisense polynucleotides, and by suppression of endogenous zvegf3
expression through knock/out techniques. Viral delivery systems (disclosed
above) can be employed. Zvegf3 antagonists can be administered or expressed
individually, in combination with other zvegf3 antagonists, or in
combination other compounds, including other growth factor antagonists. Test
animals are monitored for changes in such parameters as clinical signs, body
weight, blood cell counts, clinical chemistry, histopathology, and the like.
Effects of zvegf3 antagonists on liver and kidney fibrosis can be tested in
known animal models, such as the db/db mouse model disclosed by Cohen et
al., Diabetologia 39:270-274, 1996 and Cohen et al., J. Clin.
Invest. 95:2338-2345, 1995, transgenic animal models (Imai et al.,
Contrib. Nephrol. 107:205-215, 1994), and the CCl4-induced
cirrhosis model (Rojkind and Greenwel, Adv. Vet. Sci. Comp. Med.
37:333-355, 1993; Diaz-Gil et al., J. Hepatol. 30:1065-1072, 1999).
Effects on lung fibrosis can be assayed in a mouse model using bleomycin.
The chemotherapy agent bleomycin is a known causative agent of pulmonary
fibrosis in humans and can induce interstitial lung disease in mice,
including an increase in the number of fibroblasts, enhanced collagen
deposition, and dysregulated matrix remodeling. C57B1/6 mice are
administered bleomycin by osmotic minipump for 1 week. There follows a
period of inflammation, with cutaneous toxicity beginning approximately 4-7
days after bleomycin administration and continuing for about a week, after
which the mice appear to regain health. About 3-4 weeks after the finish of
bleomycin delivery, the mice are sacrificed, and the lungs are examined
histologically for signs of fibrosis. Scoring is based on the extent of lung
fibrotic lesions and their severity. Serum is assayed for lactic
dehydrogenase, an intracellular enzyme that is released into the circulation
upon general cell death or injury. Lung tissue is assayed for hydroxyproline
as a measure of collagen deposition.
Claim 1 of 20 Claims
1. A method of reducing cell proliferation or extracellular matrix
production caused by zvegf3 in a mammal comprising administering to the
mammal a composition comprising a zvegf3 antagonist in combination with a
pharmaceutically acceptable delivery vehicle, in an amount sufficient to
reduce zvegf3 activity, wherein said zvegf3 antagonist is an antibody that
specifically binds to a dimeric protein consisting of two polypeptide
chains, wherein each of said polypeptide chains consists of a sequence of
amino acid residues selected from the group consisting of:
residues 230-345 of SEQ ID NO:2;
residues 231-345 of SEQ ID NO:2;
residues 232-345 of SEQ ID NO:2;
residues 233-345 of SEQ ID NO:2;
residues 234-345 of SEQ ID NO:2;
residues 235-345 of SEQ ID NO:2;
residues 236-345 of SEQ ID NO:2;
residues 237-345 of SEQ ID NO:2;
residues 238-345 of SEQ ID NO:2;
residues 239-345 of SEQ ID NO:2; and
residues 240-345 of SEQ ID NO:2,
whereby administration of the composition to the mammal results in
reduction of cell proliferation or extracellular matrix production caused
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full